Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Published on October 11, 2010 at 8:41 AM · No Comments

Eli Lilly and Company (NYSE: LLY) announced today that its global Phase III trial evaluating ALIMTA® (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).

The Phase III study, the largest trial conducted in SCCHN to date, evaluated ALIMTA in combination with cisplatin compared with placebo plus cisplatin given every three weeks in a total of 795 patients. The primary objective of the study was to determine overall survival. Patient quality of life was also assessed, in addition to several pre-planned sub-group analyses.

The ALIMTA/cisplatin regimen showed a median overall survival of 7.3 months compared with 6.3 months with cisplatin alone, a result not considered a statistically significant improvement>

As a result, Lilly will not be submitting marketing authorization applications for ALIMTA in SCCHN with either the U.S. Food and Drug Administration (FDA) or the European Medicine Agency (EMA).

"The fact that combination treatment with pemetrexed and cisplatin did not improve overall survival in this study is disappointing, although perhaps not surprising given how difficult it can be to effectively treat metastatic or locally advanced head and neck cancer," said the study's principal investigator, Professor Susan Urba, M.D., Division of Hematology/Oncology, University of Michigan Comprehensive Cancer Center, USA. "We did, however, gain valuable information in this large study, which we hope will help us plan even better future trials for head and neck cancer."

Out of the nine pre-planned subgroup analyses, two showed survival advantage, which may be of clinical interest.

First, in the analysis of 690 patients with ECOG performance status of 0 or 1, those treated with the ALIMTA/cisplatin had a longer overall survival than those treated with cisplatin alone (8.4 vs. 6.7 months,>

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Filipino | Ελληνικά | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment